Impact of state Medicaid expansion on practice performance in the Enhancing Oncology Model.

196 Background: The Enhancing Oncology Model (EOM) drives health equity via increased monthly payments for dual-eligible beneficiaries, and an enhanced financial benchmark. The benchmark price includes a nearly equivalent adjustment for patients who are not dual-eligible but have Part D Low-Income Subsidy (LIS); this covers non-expansion states. However, the LIS covariate is not applied to lung and prostate cancer episodes. We explore how this methodological gap impacts practices situated in high-poverty states. Methods: We modeled a practice with 1,000 oncology episodes, a cancer type distribution of 20% lung cancer and 11% prostate cancer (observed during the EOM’s first performance period), and used CMS data on average monthly Medicaid and Medicare eligibility to calculate the share of full-dual and LIS eligible beneficiaries. We approximated the impact on episode benchmarks by multiplying these figures by the published Part D coefficients for dual-eligible and LIS status. Results: Within the 10 states with the highest estimated LIS episodes, we find that the impact of the benchmark adjustment ranges from 0.25% to 0.5% of the total episode cost - an underestimate of the true effect, given that only baseline costs are considered. Notably, most of the top ten states have a higher proportion of residents below 150% of the federal poverty level compared to the national average. Half of these states have not adopted Medicaid expansion. Conclusions: Promoting health equity is a core objective of the EOM program. However, the financial performance methodology may unintentionally penalize practices in low-income states, many of which have not expanded Medicaid - an unfortunate dual penalty. State Estimated % full dual episodes Estimated % LIS Change in the episode baseline % of all episode costs Percent below <150% of Poverty Percent below <150% of Poverty versus the national average Medicaid Expansion Status Connecticut 5.89% 11.25% $267,751 0.44% 15.80% -4.40% Adopted Alabama 6.72% 9.93% $239,128 0.39% 25.20% 5.00% Not adopted Mississippi 9.67% 9.68% $233,303 0.38% 30.20% 10.00% Not adopted Maine 13.07% 8.95% $216,330 0.36% 18.20% -2.00% Adopted Georgia 6.06% 8.45% $199,357 0.33% 22.10% 1.90% Not adopted Florida 9.91% 7.53% $176,559 0.29% 21.30% 1.10% Not adopted West Virginia 8.56% 6.46% $153,761 0.25% 26.30% 6.10% Adopted Tennessee 9.31% 6.16% $147,936 0.24% 22.70% 2.50% Not adopted Louisiana 7.57% 6.08% $147,936 0.24% 28.60% 8.40% Adopted New Mexico 5.94% 5.89% $147,936 0.24% 28.50% 8.30% Adopted

Authors

Institutions

Publication Details

Journal
JCO Oncology Practice
Published
2025-10-01
DOI
https://doi.org/10.1200/op.2025.21.10_suppl.196
Primary Topic
Economic and Financial Impacts of Cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Impact of state Medicaid expansion on practice performance in the Enhancing Oncology Model.

Alphan Kirayoglu, Robert Jeffrey Green, Kesshi Jordan, Puneeth Indurlal et al.
JCO Oncology Practice
Economic and Financial Impacts of Cancer
article

Impact of state Medicaid expansion on practice performance in the Enhancing Oncology Model.

Alphan Kirayoglu, Robert Jeffrey Green, Kesshi Jordan, Puneeth Indurlal, Samyukta Mullangi, Lalan S. Wilfong, Stephen G. Divers
article en

Abstract

196 Background: The Enhancing Oncology Model (EOM) drives health equity via increased monthly payments for dual-eligible beneficiaries, and an enhanced financial benchmark. The benchmark price includes a nearly equivalent adjustment for patients who are not dual-eligible but have Part D Low-Income Subsidy (LIS); this covers non-expansion states. However, the LIS covariate is not applied to lung and prostate cancer episodes. We explore how this methodological gap impacts practices situated in high-poverty states. Methods: We modeled a practice with 1,000 oncology episodes, a cancer type distribution of 20% lung cancer and 11% prostate cancer (observed during the EOM’s first performance period), and used CMS data on average monthly Medicaid and Medicare eligibility to calculate the share of full-dual and LIS eligible beneficiaries. We approximated the impact on episode benchmarks by multiplying these figures by the published Part D coefficients for dual-eligible and LIS status. Results: Within the 10 states with the highest estimated LIS episodes, we find that the impact of the benchmark adjustment ranges from 0.25% to 0.5% of the total episode cost - an underestimate of the true effect, given that only baseline costs are considered. Notably, most of the top ten states have a higher proportion of residents below 150% of the federal poverty level compared to the national average. Half of these states have not adopted Medicaid expansion. Conclusions: Promoting health equity is a core objective of the EOM program. However, the financial performance methodology may unintentionally penalize practices in low-income states, many of which have not expanded Medicaid - an unfortunate dual penalty. State Estimated % full dual episodes Estimated % LIS Change in the episode baseline % of all episode costs Percent below <150% of Poverty Percent below <150% of Poverty versus the national average Medicaid Expansion Status Connecticut 5.89% 11.25% $267,751 0.44% 15.80% -4.40% Adopted Alabama 6.72% 9.93% $239,128 0.39% 25.20% 5.00% Not adopted Mississippi 9.67% 9.68% $233,303 0.38% 30.20% 10.00% Not adopted Maine 13.07% 8.95% $216,330 0.36% 18.20% -2.00% Adopted Georgia 6.06% 8.45% $199,357 0.33% 22.10% 1.90% Not adopted Florida 9.91% 7.53% $176,559 0.29% 21.30% 1.10% Not adopted West Virginia 8.56% 6.46% $153,761 0.25% 26.30% 6.10% Adopted Tennessee 9.31% 6.16% $147,936 0.24% 22.70% 2.50% Not adopted Louisiana 7.57% 6.08% $147,936 0.24% 28.60% 8.40% Adopted New Mexico 5.94% 5.89% $147,936 0.24% 28.50% 8.30% Adopted

JCO Oncology PracticeVol. 21(10_suppl)
New York Laser and Skin Care (US), Institute for Patient- and Family-Centered Care (US), The US Oncology Network (US)
Openalex Percentile: Top 63%
Economic and Financial Impacts of Cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.